IBISWorld Platform
Answer any industry question in minutes with our entire database at your fingertips.
Biotechnology is becoming an increasingly important part of product development in a variety of sectors, with businesses using biotech applications to address many social and economic issues, including human health, food security and alternative fuels. Several companies have reached commercial readiness, with robust product pipelines and support from international partners improving their attractiveness to investors. While human therapeutics companies continue to dominate the industry, agricultural technology and food technology companies are gaining momentum. New funding sources are helping to drive industry growth.
Answer any industry question in minutes with our entire database at your fingertips.
Feed trusted, human-driven industry intelligence straight into your platform.
Streamline your workflow with IBISWorld’s intelligence built into your toolkit.
IBISWorld's research coverage on the Biotechnology industry in Australia includes market sizing, forecasting, data and analysis from 2015-2030. The most recent publication was released May 2025.
The Biotechnology industry in Australia operates under the ANZSIC industry code X0001. Biotechnology involves applying science and technology to living organisms, and parts, products and models, to alter living or non-living materials to produce knowledge and biotechnology products and services. The industry includes biotechnology research and development, licensing, product manufacturing and product wholesaling. Companies that focus on medical devices are not included in the industry. Related terms covered in the Biotechnology industry in Australia include genetic modification (gm), venture capital, gene therapy, angel investors, biomining, biologicals and biosimilars.
Products and services covered in Biotechnology industry in Australia include Other products and services, Environmental and natural resource recovery and Human health biotechnology.
Companies covered in the Biotechnology industry in Australia include CSL, Telix and CSIRO.
The Performance chapter covers detailed analysis, datasets, detailed current performance, sources of volatility and an outlook with forecasts for the Biotechnology industry in Australia.
Questions answered in this chapter include what's driving current industry performance, what influences industry volatility, how do successful businesses overcome volatility, what's driving the industry outlook. This analysis is supported with data and statistics on industry revenues, costs, profits, businesses and employees.
The Products and Markets chapter covers detailed products and service segmentation and analysis of major markets for the for the Biotechnology industry in Australia.
Questions answered in this chapter include how are the industry's products and services performing, what are innovations in industry products and services, what products or services do successful businesses offer and what's influencing demand from the industry's markets. This includes data and statistics on industry revenues by product and service segmentation and major markets.
The Geographic Breakdown chapter covers detailed analysis and datasets on regional performance of the Biotechnology industry in Australia.
Questions answered in this chapter include where are industry businesses located and how do businesses use location to their advantage. This includes data and statistics on industry revenues by location.
The Competitive Forces chapter covers the concentration, barriers to entry and supplier and buyer profiles in the Biotechnology industry in Australia. This includes data and statistics on industry market share concentration, barriers to entry, substitute products and buyer & supplier power.
Questions answered in this chapter include what impacts the industry's market share concentration, how do successful businesses handle concentration, what challenges do potential industry entrants face, how can potential entrants overcome barriers to entry, what are substitutes for industry services, how do successful businesses compete with substitutes and what power do buyers and suppliers have over the industry and how do successful businesses manage buyer & supplier power.
The Companies chapter covers Key Takeaways, Market Share and Companies in the Biotechnology industry in Australia. This includes data and analysis on companies operating in the industry that hold a market share greater than 5%.
Questions answered in this chapter include what companies have a meaningful market share and how each company is performing.
The External Environment chapter covers Key Takeaways, External Drivers, Regulation & Policy and Assistance in the Biotechnology industry in Australia. This includes data and statistics on factors impacting industry revenue such as economic indicators, regulation, policy and assistance programs.
Questions answered in this chapter include what demographic and macroeconomic factors impact the industry, what regulations impact the industry, what assistance is available to this industry.
The Financial Benchmarks chapter covers Key Takeaways, Cost Structure, Financial Ratios, Valuation Multiples and Key Ratios in the Biotechnology industry in Australia. This includes financial data and statistics on industry performance including key cost inputs, profitability, key financial ratios and enterprise value multiples.
Questions answered in this chapter include what trends impact industry costs and how financial ratios have changed overtime.
The Industry Data chapter includes 10 years of historical data with 5 years of forecast data covering statistics like revenue, industry value add, establishments, enterprises, employment and wages in the Biotechnology industry in Australia.
More than 6,000 businesses use IBISWorld to shape local and global economies
We were able to supplement our reports with IBISWorld’s information from both a qualitative and quantitative standpoint. All of our reporting now features some level of IBISWorld integration.
IBISWorld delivers the crisp business knowledge we need to drive our business. Whether it be serving up our major clients, winning new business or educating on industry issues, IBISWorld brings real value.
IBISWorld has revolutionised business information — which has proved commercially invaluable to exporters, investors and public policy professionals in Australia and overseas.
When you’re able to speak to clients and be knowledgeable about what they do and the state that they operate in, they’re going to trust you a lot more.
The market size of the Biotechnology industry in Australia is $12.3bn in 2026.
There are 930 businesses in the Biotechnology industry in Australia, which has grown at a CAGR of 7.8 % between 2020 and 2025.
The Biotechnology industry in Australia is unlikely to be materially impacted by import tariffs with imports accounting for a low share of industry revenue.
The Biotechnology industry in Australia is unlikely to be materially impacted by export tariffs with exports accounting for a low share of industry revenue.
The market size of the Biotechnology industry in Australia has been growing at a CAGR of 2.4 % between 2020 and 2025.
Over the next five years, the Biotechnology industry in Australia is expected to grow.
The biggest companies operating in the Biotechnology industry in Australia are CSL, Telix and CSIRO
Human health biotechnology and Agricultural biotechnology are part of the Biotechnology industry in Australia.
The company holding the most market share in the Biotechnology industry in Australia is CSL.
The level of competition is moderate and increasing in the Biotechnology industry in Australia.